RA CAPITAL MANAGEMENT, L.P.

Position in BCAX — Bicara Therapeutics Inc.

CIK 1346824 BOSTON, MA

Position in BCAX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$144,321,700

+$27,252,338 QoQ

Shares Held

7,255,993

+4.3% QoQ

Ownership

11.0%

of shares outstanding

% of Portfolio

1.53%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2024

7 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

RA CAPITAL MANAGEMENT, L.P. holds $9,134,713,488 across 74 Biotechnology names. BCAX ranks #16 (1.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	10,281,496	$2,351,686,580
2	PCVX	Vaxcyte, Inc.	11,474,599	$666,788,947
3	RYTM	Rhythm Pharmaceuticals, Inc.	6,666,837	$579,814,813
4	TYRA	Tyra Biosciences, Inc.	12,198,625	$467,207,337
5	SION	Sionna Therapeutics, Inc.	9,905,045	$397,093,254
6	EWTX	Edgewise Therapeutics, Inc.	10,428,437	$328,495,765
7	NAMS	NewAmsterdam Pharma Co N.V.	9,550,191	$305,701,613
8	NUVL	Nuvalent, Inc.	2,534,145	$259,623,155

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$144,321,700	7,255,993	-0.3%	Shares	Sole	2026-05-15
2026-02-26	$122,299,615	7,279,739	+4.7%	Shares	Sole	2026-03-02
2025-12-31	$117,069,362	6,955,993	0.0%	Shares	Sole	2026-02-17
2025-09-30	$109,835,129	6,955,993	0.0%	Shares	Sole	2025-11-14
2025-06-30	$64,621,174	6,955,993	0.0%	Shares	Sole	2025-08-14
2025-03-31	$90,636,588	6,955,993	0.0%	Shares	Sole	2025-05-15
2024-12-31	$121,173,398	6,955,993	0.0%	Shares	Sole	2025-02-14
2024-09-30	$177,169,141	6,955,993	—	Shares	Sole	2024-11-14
No filing history on record for this holder in this stock.